Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in moderate to severe atopic dermatitis
NCT03349060Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started Dec 2017; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03349060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349060.